Ken Griffin Lineage Cell Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$0.8 - $1.12 $26,000 - $36,400	32,500 Added 103.83%	63,800 $58,000
Q2 2024 Aug 14, 2024	BUY	$0.89 - $1.47 $8,811 - $14,553	9,900 Added 46.26%	31,300 $31,000
Q1 2024 May 15, 2024	BUY	$0.86 - $1.48 $15,566 - $26,788	18,100 Added 548.48%	21,400 $31,000
Q4 2023 Feb 14, 2024	SELL	$0.91 - $1.35 $11,375 - $16,875	-12,500 Reduced 79.11%	3,300 $3,000
Q3 2023 Nov 14, 2023	BUY	$1.16 - $1.53 $12,412 - $16,371	10,700 Added 209.8%	15,800 $18,000
Q2 2023 Aug 14, 2023	SELL	$1.26 - $1.53 $22,932 - $27,846	-18,200 Reduced 78.11%	5,100 $7,000
Q1 2023 May 15, 2023	BUY	$1.2 - $1.53 $8,160 - $10,404	6,800 Added 41.21%	23,300 $34,000
Q4 2022 Feb 14, 2023	BUY	$1.02 - $1.5 $16,830 - $24,750	16,500 New	16,500 $19,000

121

94.2M

63.8K

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $96.8M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.